Q3 FY2026 · ended Sep 30, 2026 · Revenue $53.23M, +1.8% YoY · Filed Nov 4, 2026
Cytek Biosciences, Inc. (CTKB) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $53.2 million and a net loss of $6.1 million. Free cash flow was -$6.0 million. As of Sep 30, 2026 it held $255.9 million in cash and investments and $16.2 million in total debt.
Revenue
$53.23M
+1.8% vs year-ago quarter
Net income
$-6.10M
+49.9% vs prior quarter
Operating cash flow
$-4.45M
-14.2% vs year-ago quarter
Free cash flow
$-5.96M
-30.8% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
130.78M
+2.3% vs year-ago quarter
Net cash
$239.66M
Q3 FY2026
Operating margin
-21.1%
TTM
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- CTKB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fremont, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1831915
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $53.2M | $48.1M | $44.1M | $62.1M | $52.3M |
| Operating income | -$8.4M | -$11.4M | -$18.5M | -$5.6M | -$9.2M |
| Net income | -$6.1M | -$12.2M | -$18.9M | — | — |
| Operating cash flow | -$4.5M | $1.4M | -$2.7M | -$771,000 | -$3.9M |
| Free cash flow | -$6.0M | -$849,000 | -$4.9M | -$1.8M | -$4.6M |
| Total assets | $446.1M | $446.9M | $449.1M | $461.5M | $494.9M |
| Total liabilities | $124.8M | $125.0M | $121.5M | $119.8M | $116.3M |
| Stockholders' equity | $321.4M | $322.0M | $327.6M | $341.7M | $378.6M |
| Cash and investments | $255.9M | $262.0M | $262.2M | $261.5M | $261.7M |
| Total debt | $16.2M | $16.8M | $16.4M | $16.9M | $16.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 24, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 464 Cytek Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.